Azitra Inc AZTR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
-
Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
-
Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
Trading Information
- Previous Close Price
- $0.15
- Day Range
- $0.15–0.15
- 52-Week Range
- $0.10–1.69
- Bid/Ask
- $0.15 / $0.15
- Shares Outstanding
- 16.19M
- Market Cap
- $2.41M
- Volume/Avg
- 148,449 / 11M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.azitrainc.com
Valuation
|
Metric
|
AZTR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.23 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AZTR
|
|---|---|
Quick Ratio | 6.59 |
Current Ratio | 6.94 |
Interest Coverage | −1,220.40 |
Quick Ratio
AZTR
Profitability
|
Metric
|
AZTR
|
|---|---|
Return on Assets (Normalized) | −188.10% |
Return on Equity (Normalized) | −253.94% |
Return on Invested Capital (Normalized) | −231.47% |
Return on Assets
AZTR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|sVGdFJf | LOCK|%rv? | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|sLg^$w$ | LOCK|l#^Q | $70B | |||
| argenx SE ADR
ARGX
| LOCK|bnH#x& | LOCK|!q | $57B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|J?t?rR | LOCK|K>sqZ | $42B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#$Nw<c | LOCK|fk | $35B | |||
| Moderna Inc
MRNA
| LOCK|fsbDt>! | LOCK|s^ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^$%<xVlP | LOCK|n<^Z | $26B | |||
| Incyte Corp
INCY
| LOCK|$JtDk%J | LOCK|$!& | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|JrDTQ% | LOCK|!>@ | $24B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|n!$?vr | LOCK|Xp | $18B |
United States